Kyowa Hakko Kirin Files For Additional Indication For NESP
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin has filed for approval of their long-acting erythropoiesis-stimulating agent NESP (darbepoetin alpha gene recombinant) for treatment of anemia associated with myelodysplastic syndrome in Japan, the company announced on March 31.